SYNCOMF
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Syncom Formulations (India) Says Rahul Vijay Bankda Appointed As CFO Effective August 9
Aug 8 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
SYNCOM FORMULATIONS (INDIA) LTD - RAHUL VIJAY BANKDA APPOINTED AS CFO EFFECTIVE AUGUST 09, 2025
Source text: ID:nBSE4BsXyS
Further company coverage: SYFI.NS
(([email protected];))
Aug 8 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
SYNCOM FORMULATIONS (INDIA) LTD - RAHUL VIJAY BANKDA APPOINTED AS CFO EFFECTIVE AUGUST 09, 2025
Source text: ID:nBSE4BsXyS
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) To Commence Manufacturing, Marketing Of Generic Products
Aug 30 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
SYNCOM FORMULATIONS (INDIA) - TO COMMENCE MANUFACTURING, MARKETING OF GENERIC PRODUCTS
Further company coverage: SYFI.NS
(([email protected];))
Aug 30 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
SYNCOM FORMULATIONS (INDIA) - TO COMMENCE MANUFACTURING, MARKETING OF GENERIC PRODUCTS
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) Re-Appoints Kedarmal Shankarlal Bankda As Chairman
Aug 12 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
RE-APPOINTS KEDARMAL SHANKARLAL BANKDA AS CHAIRMAN
Further company coverage: SYFI.NS
(([email protected];))
Aug 12 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
RE-APPOINTS KEDARMAL SHANKARLAL BANKDA AS CHAIRMAN
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) Commences Commercial Production In Pithampur Plant
Aug 21 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
COMMENCED COMMERCIAL PRODUCTION IN PITHAMPUR PLANT
Source text for Eikon: ID:nBSE6gLJQY
Further company coverage: SYFI.NS
(([email protected];))
Aug 21 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
COMMENCED COMMERCIAL PRODUCTION IN PITHAMPUR PLANT
Source text for Eikon: ID:nBSE6gLJQY
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) June-Quarter Consol Profit Rises
Aug 14 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
JUNE-QUARTER CONSOL PROFIT 44 MILLION RUPEES VERSUS PROFIT 38.7 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 598.4 MILLION RUPEES VERSUS 514 MILLION RUPEES
Source text for Eikon: ID:nBSE5Bwbv7
Further company coverage: SYFI.NS
(([email protected];;))
Aug 14 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
JUNE-QUARTER CONSOL PROFIT 44 MILLION RUPEES VERSUS PROFIT 38.7 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 598.4 MILLION RUPEES VERSUS 514 MILLION RUPEES
Source text for Eikon: ID:nBSE5Bwbv7
Further company coverage: SYFI.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Syncom Formulations do?
Syncom Formulations (India) Ltd. specializes in manufacturing and marketing a wide range of pharmaceutical products in various dosage forms such as tablets, capsules, liquids, injectibles, and herbal products.
Who are the competitors of Syncom Formulations?
Syncom Formulations major competitors are Jagsonpal Pharma, Beta Drugs, Kwality Pharma, Venus Remedies, Lincoln Pharma, Bliss GVS Pharma, Sakar Healthcare. Market Cap of Syncom Formulations is ₹1,398 Crs. While the median market cap of its peers are ₹1,171 Crs.
Is Syncom Formulations financially stable compared to its competitors?
Syncom Formulations seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Syncom Formulations pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Syncom Formulations latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Syncom Formulations allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Syncom Formulations balance sheet?
Balance sheet of Syncom Formulations is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Syncom Formulations improving?
Yes, profit is increasing. The profit of Syncom Formulations is ₹63.05 Crs for TTM, ₹49.43 Crs for Mar 2025 and ₹25.31 Crs for Mar 2024.
Is the debt of Syncom Formulations increasing or decreasing?
The net debt of Syncom Formulations is decreasing. Latest net debt of Syncom Formulations is -₹0.58 Crs as of Sep-25. This is less than Mar-25 when it was ₹3.3 Crs.
Is Syncom Formulations stock expensive?
Syncom Formulations is not expensive. Latest PE of Syncom Formulations is 22.17, while 3 year average PE is 45.0. Also latest EV/EBITDA of Syncom Formulations is 20.95 while 3yr average is 42.7.
Has the share price of Syncom Formulations grown faster than its competition?
Syncom Formulations has given lower returns compared to its competitors. Syncom Formulations has grown at ~29.38% over the last 8yrs while peers have grown at a median rate of 29.57%
Is the promoter bullish about Syncom Formulations?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Syncom Formulations is 50.57% and last quarter promoter holding is 50.57%.
Are mutual funds buying/selling Syncom Formulations?
There is Insufficient data to gauge this.
